- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04606381
Исследование подкожного (п/к) введения амивантамаба для лечения запущенных солидных злокачественных новообразований (PALOMA)
Открытое многоцентровое исследование фазы 1b с повышением дозы для оценки безопасности и фармакокинетики подкожного введения амивантамаба, человеческого биспецифического EGFR и антитела cMet для лечения запущенных солидных злокачественных новообразований
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
Ontario
-
Toronto, Ontario, Канада, M5G 2M9
- University Health Network
-
-
-
-
-
Manchester, Соединенное Королевство, M20 4BX
- The Christie Nhs Foundation Trust
-
Sutton, Соединенное Королевство, SM2 5PT
- Royal Marsden Hospital
-
-
-
-
California
-
West Hollywood, California, Соединенные Штаты, 90048
- Cedars Sinai Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46256
- Community Health Network
-
-
New York
-
New York, New York, Соединенные Штаты, 10016
- Langone Health at NYC University, NYU School of Medicine
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97213
- Providence Portland Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Sarah Cannon Research Institute
-
-
-
-
-
Cheongju-si, Южная Корея, 28644
- Chungbuk National University Hospital
-
Seongnam-si, Южная Корея, 13620
- Seoul National University Bundang Hospital
-
Seoul, Южная Корея, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Южная Корея, 06351
- Samsung Medical Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion criteria:
- Part 1 and Part 2: Participant must have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and which may derive benefit from epidermal growth factor receptor (EGFR) or mesenchymal-epidermal transition tyrosine kinase receptor/hepatocyte growth factor receptor (cMet) directed therapy. Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC). Participants must have either progressed after prior standard of care therapy for metastatic disease, be ineligible for, or have refused all other currently available therapeutic options. In cases where participants refuse currently available therapeutic options, this must be documented in the study records.
- Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine or serum pregnancy test within 24 hours before the first dose of study drug
- A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug
- A man who is sexually active with a woman of childbearing potential must agree to use a condom and his partner must also be practicing a highly effective method of contraception (that is, established use of oral, injected or implanted hormonal methods of contraception; placement of an Intrauterine device [IUD] or Intrauterine system [IUS])
Exclusion criteria:
- Participant has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active systemic infection (that is, has discontinued all antibiotics for at least one week prior to first dose of study drug), diagnosed or suspected viral infection (except Human immunodeficiency virus [HIV] positive participants with 1 or more of the following: a) not receiving highly active antiretroviral therapy; b) a change in antiretroviral therapy within 6 months of the start of screening; c) cluster of differentiation 4 (CD4)+ T-cell count less than [<]350 per cubic millimeters [mm^3] at screening; d) an acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening), or psychiatric illness/social situation that would limit compliance with study requirements, including ability to self-care for anticipated toxicities [that is. rash or paronychia]. Participants with medical conditions requiring chronic continuous oxygen therapy are excluded
- Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study drug; or participant has received prior immunotherapy within 6 weeks before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline levels
- Participants with untreated brain metastases. Participants with locally treated metastases that are clinically stable and asymptomatic for at least 2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 milligrams [mg] prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible
- Participant has an active malignancy other than the disease under study requiring treatment
- Participant has leptomeningeal disease
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Part 1: Ami-LC-MD and Ami-LC
Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion. |
Participants will receive amivantamab admixed with rHuPH20 SC infusion. Participants will receive amivantamab SC infusion. |
|
Экспериментальный: Part 2: Ami-HC and Ami-HC-CF
Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or SC injection of amivantamab co-formulated with rHuPH20 (Ami-HC-CF). |
Participants will receive amivantamab SC infusion. Participants will receive amivantamab co-formulated with rHuPH20 as SC injection. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)
Временное ограничение: Up to Day 29
|
Ctrough is the observed amivantamab serum concentration immediately prior to the next drug administration. |
Up to Day 29
|
|
Number of Participants with Adverse Event (AE)
Временное ограничение: Up to 4 years 1 month
|
An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. |
Up to 4 years 1 month
|
|
Number of Participants with Dose Limiting Toxicity (DLT)
Временное ограничение: Up to Day 28
|
Number of participants with DLT will be assessed. |
Up to Day 28
|
|
Number of Participants with Clinical Laboratory Abnormalities
Временное ограничение: Up to 4 years 1 month
|
Number of participants with clinical laboratory (hematology, clinical chemistry, and urinalysis) abnormalities will be assessed. |
Up to 4 years 1 month
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of Participants with Anti-amivantamab and Anti-rHuPH20 antibodies
Временное ограничение: Up to 4 years 1 month
|
Number of participants with anti-amivantamab and anti-rHuPH20 antibodies will be assessed. |
Up to 4 years 1 month
|
|
Epidermal Growth Factor Receptor (EGFR) Concentrations
Временное ограничение: Up to 4 years 1 month
|
EGRF concentrations markers will be assessed. |
Up to 4 years 1 month
|
|
Mesenchymal-Epidermal Transition Tyrosine Kinase Receptor/Hepatocyte Growth Factor Receptor (cMET) Markers
Временное ограничение: Up to 4 years 1 month
|
cMET markers will be analyzed. |
Up to 4 years 1 month
|
|
Overall Response Rate (ORR)
Временное ограничение: Up to 4 years 1 month
|
ORR defined as the proportion of participants with partial response (PR) or better according to Response Criteria in Solid Tumors (RECIST) v1.1. |
Up to 4 years 1 month
|
|
Part 2: Maximum Amivantamab Dosing Interval Between Time Zero to Steady State
Временное ограничение: Up to 4 years 1 month
|
Maximum amivantamab dosing interval Between time zero to steady state will be assessed. |
Up to 4 years 1 month
|
Соавторы и исследователи
Следователи
- Директор по исследованиям: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CR108891
- 2020-003225-36 (Номер EudraCT)
- 61186372NSC1003 (Другой идентификатор: Janssen Research & Development, LLC)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .